A PYMNTS Company

US: Court to hear Actavis appeal

By  |  April 12, 2015

Actavis today confirmed that the United States Court of Appeals for the Federal Circuit has granted AstraZeneca’s request for an injunction pending appeal preventing Actavis from further distribution of its generic version of Pulmicort.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Under the ruling, Actavis’ sales of generic Pulmicort have been enjoined pending the resolution of AstraZeneca’s appeal before the Court. The Court has set an expedited briefing schedule for the appeal, with expedited briefing to be concluded within 33 days. The injunction does not address product shipped prior to its issuance.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

     

    Full Content: The AM Law Litigation Daily

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.